However, high-dose therapy may lead to grade 4 neutropenia and hypoxemia.54 In a phase I/II study, IFN-γ in combination with carboplatin and paclitaxel was applied to treat patients with advanced ovarian cancer and reached a 71% overall response rate. This evidence concerns the gene IFNG and ovarian carcinoma.